Incidence and duration of antidepressant-induced nausea: Duloxetine compared with paroxetine and fluoxetine

Clinical Therapeutics

Volumn 26, Issue 9, 2004, Pages 1446-1455

  Greist, John ^a   McNamara, Robert K ^b   Mallinckrodt, Craig H ^c   Rayamajhi, Jyoti N ^c   Raskin, Joel ^c  

^a Healthcare Technology Systems Inc   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

antidepressant; duloxetine; fluoxetine; MDD; nausea; norepinephrine; paroxetine; serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; FLUOXETINE; PAROXETINE; PLACEBO;

ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INCIDENCE; MAJOR DEPRESSION; MALE; NAUSEA; STATISTICAL SIGNIFICANCE; VOMITING;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; EUROPE; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; NAUSEA; PAROXETINE; PREVALENCE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; THIOPHENES; TIME FACTORS; UNITED STATES;

EID: 9744219679     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.09.010     Document Type: Article

References (37)

1. Miller A.D., and Leslie R.A. The area postrema and vomiting Front Neuroendocrinol 15 1994 301 320
2. 3 receptors Neuropharmacology 31 1992 735 742
3. Bhargava K.P., Dixit K.S., and Palit G. Nature of histamine receptors in the emetic chemoreceptor trigger zone Br J Pharmacol 57 1976 211 213
4. Cubeddu L.X., Hoffmann I.S., Fuenmayor N.T., and Finn A.L. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting N Engl J Med 322 1990 810 816
5. (Suppl) Hasler W.L. Serotonin receptor physiology: Relation to emesis Dig Dis Sci 44 1999 108S 113S
6. McManis P.G., and Talley T.J. Nausea and vomiting associated with selective serotonin reuptake inhibitors: Incidence, mechanisms, and management CNS Drugs 8 1997 394 401
7. Mackay F.R., Dunn N.R., and Martin R.M. Newer antidepressants: A comparison of tolerability in general practice Br J Gen Pract 49 1999 892 896
8. Beasley C.M. Jr., Koke S.C., Nilsson M.E., and Gonzales J.S. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis Clin Ther 22 2000 1319 1330
9. Ueda N., Yoshimura R., and Shinkai K. Characteristics of fluvoxamine-induced nausea Psychiatry Res 104 2001 259 264
10. Bergeron R., and Blier P. Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors Am J Psychiatry 151 1994 1084 1086
11. 3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin reuptake inhibitor in man J Psychopharmacol 9 1995 137 141
12. Bymaster F.P., Dreshfield-Ahmad L.J., and Threlkeld P.G. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors Neuropsychopharmacology 25 2001 871 880
13. Turcotte J.E., Debonnel G., and de Montigny C. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects Neuropsychopharmacology 24 2001 511 521
14. Chalon S.A., Granier L.A., and Vandenhende F.R. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: A double-blind, con trolled study Neuropsychophannacology 28 2003 1685 1693
15. Detke M.J., Lu Y., and Goldstein D.J. Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial J Clin Psychiatry 63 2002 308 315
16. Detke M.J., Lu Y., and Goldstein D.J. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression J Psychiatr Res 36 2002 383 390
17. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo and active comparator-controlled trial. Eur Neuropsychophannacol. In press.
18. Goldstein D.J., Mallinckrodt C., and Lu Y. Duloxetine in the treatment of major depressive disorder: A doubleblind clinical trial J Clin Psychiatry 63 2002 225 231
19. Nemeroff C.B., Schatzberg A.F., and Goldstein D.J. Duloxetine for the treatment of major depressive disorder Psychopharmacol Bull 36 2002 106 132
20. Norton P.A., Zinner N.R., Yalcin I. Duloxetine Urinary Incontinence Study Group Duloxetine versus placebo in the treatment of stress urinary incontinence Am J Obstet Gynecol 187 2002 40 48
21. Goldstein D.J., Lu Y., and Detke M.J. Duloxetine in the treatment of depression: A double-blind placebocontrolled comparison with paroxetine J Clin Psychopharmacol 24 2004 389 399
22. American Psychiatric Association Fourth Edition Diagnostic and Statistical Manual of Mental Disorders 1994 American Psychiatric Association Washington, DC
23. Available at: World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects Accessed July 29, 2004
24. Available at: US Food and Drug Administration Good clinical practice in FDA-regulated clinical trials Accessed July 29, 2004
25. Barsky A.J., Wyshak G., and Klerman G.L. Hypochondriasis. An evaluation of the DSM-III criteria in medical outpatients Arch Gen Psychiatry 43 1986 493 500
26. Haug T.T., Mykletun A., and Dahl A.A. The prevalence of nausea in the community: Psychological, social and somatic factors Gen Hosp Psychiatry 24 2002 81 86
27. Reimherr F.W., Amsterdam J.D., and Quitkin F.M. Optimal length of continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment Am J Psychiatry 155 1998 1247 1253
28. Raskin J., Goldstein D.J., and Mallinckrodt C. Duloxetine in the long-term treatment of major depressive disorder J Clin Psychiatry 64 2003 1237 1244
29. Golden R.N., Nemeroff C.B., and McSorley P. Efficacy and tolerability of controlled-release and immediaterelease paroxetine in the treatment of depression J Clin Psychiatry 63 2002 577 584
30. DeVane C.L. Immediate-release versus controlledrelease formulations: Pharmacokinetics of newer antidepressants in relation to nausea J Clin Psychiatry 64 Suppl 18 2003 14 19
31. Quigley E.M., Hasler W.L., and Parkman H.P. AGA technical review on nausea and vomiting Gastroenterology 120 2001 263 286
32. Wilde M.I., and Markham A. Ondansetron A review of its pharmacology and preliminary clinical findings in novel applications Drugs 52 1996 773 794
33. Lara D.R., Busnello E.D., and Souza D.O. Ondansetron rather than metoclopramide for bupropion-induced nausea Can J Psychiatry 46 2001 371
34. 3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting Can J Anaesth 47 2000 1008 1018
35. Kovac A.L. Prevention and treatment of postoperative nausea and vomiting Drugs 59 2000 213 243
36. Hamid S.K., Selby I.R., Sikich N., and Lerman J. Vomiting after adenotonsillectomy in children: A comparison of ondansetron, dimenhydrinate, and placebo Anesth Analg 86 1998 496 500
37. Fraga X.F., and Malagelada J.R. Nausea and vomiting Curr Treat Options Gastroenterol 5 2002 241 250